Sensory Organ Partnering Terms and Agreements

The Sensory Organ Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter sensory organ partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors sensory organ technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest sensory organ deals and contracts announced in the healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The report includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. The initial chapters of this report provide an orientation of sensory organ dealmaking and business activities. Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in sensory organ dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.
Chapter 3 provides a review of the leading sensory organ deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of sensory organ deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides comprehensive access to all sensory organ deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all sensory organ partnering deals signed and announced since 2007. The chapter is organized by specific sensory organ therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all sensory organ partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in sensory organ partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dermatology technologies and products.
Benefits
Key benefits
Sensory Organ Partnering Terms and Agreementsprovides the reader with the following key benefits:
• In-depth understanding of sensory organ deal trends since 2007
• Access sensory organ deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between dermatology partner companies
• Comprehensive access to over 1500 links to actual dermatology deals entered into by the world’s biopharma companies
• Indepth review of sensory organ deals entered into by the leading fifty bigpharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner dermatology opportunities
• Uncover companies actively partnering dermatology opportunities
Report scope
Dermatology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to dermatology trends and structure of deals entered into by leading companies worldwide.
Dermatology Partnering Terms and Agreements includes:
o Trends in dermatology dealmaking in the biopharma industry since 2007
o Analysis of dermatology deal structure
o Access to headline, upfront, milestone and royalty data
o Access to hundreds of dermatology deal contract documents
o Comprehensive access to over 1500 dermatology deal records
o The leading dermatology deals by value since 2007
o Most active dermatology dealmakers since 2007
In Dermatology Partnering Terms and Agreements, available deals and contracts are listed by:
o Headline value o Upfront payment value
o Royalty rate value o Stage of development at signing
o Deal component type
o Technology type
o Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
This on-demand report will be delivered by publisher within 1-3 days after receipt of order

Table of contents



Executive Summary

Chapter 1 – Introduction



Chapter 2 – Trends in sensory organ dealmaking

2.1. Introduction

2.2. Sensory organ partnering over the years

2.3. Bigpharma sensory organ dealmaking activity

2.4. Bigpharma not active in sensory organ

2.5. Sensory organ partnering by deal type

2.6. Sensory organ partnering by industry sector

2.7. Sensory organ partnering by stage of development

2.8. Sensory organ partnering by technology type

2.9. Sensory organ partnering by dermatology indication

2.10. Average deal terms for sensory organ

2.10.1 Sensory organ headline values

2.10.2 Sensory organ upfront payments

2.10.3 Sensory organ milestone payments

2.10.4 Sensory organ royalty rates



Chapter 3 – Leading sensory organ deals

3.1. Introduction

3.2. Top sensory organ deals by value

3.3. Top sensory organ deals involving bigpharma



Chapter 4 – Bigpharma sensory organ deals

4.1. Introduction

4.2. How to use bigpharma partnering deals

4.3. Bigpharma sensory organ partnering company profiles

Abbott

Actavis

Actelion

Allergan

Amgen

Astellas

AstraZeneca

Baxter International

Bayer

Bristol-Myers

Squibb C

elgene

Eli Lilly

Endo Pharmaceuticals

Forest Laboratories

Galderma

GlaxoSmithKline

Hospira

Johnson & Johnson

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Novartis

Pfizer

Roche

Sanofi

Shionogi

Shire

Teva

Warner Chilcott

Watson



Chapter 5 – Sensory organ partnering contracts directory

5.1. Introduction

5.2. By deal type

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

Development

Distribution

Equity purchase

Joint venture

Licensing

Litigation

Loan

Manufacturing

Marketing

Option

Promotion

Research

Settlement

Sub-license

Supply

Termination

5.3. By stage of development

Discovery

Formulation

Marketed

Phase I

Phase II

Phase III

Preclinical

5.4. By technology type

Antibodies

Assays

Biologicalcompounds

Biomaterials

Clinical testing

Devices

Diagnostics

DNA probes

Drug delivery

Enabling technology

Equipment

Genomics

Natural product

Oligonucleotide

Orphan drug

Peptides

Processes

Recombinant DNA

Regenerative medicine

Research services

Research supplies

Screening

Small molecules

Stem cells



Chapter 6 – Sensory organ dealmaking by indication

6.1. Introduction

6.2. Deals by therapeutic indication

Sensory organ

Taste

Hearing

Hearing loss

Meniere''s disease

Smell



Chapter 7 – Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking



Appendices

Appendix 1 – Directory of sensory organ deals by company A-Z 2007-2013

Appendix 2 – Directory of sensory organ deals by deal type 2007-2013

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Litigation

Loan

Manufacturing

Manufacturing - OEM

Marketing

Material transfer

Option

Promotion

Research

Royalty financing

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

Appendix 3 - Directory of sensory organ deals by stage of development 2007-2013

Appendix 4 – Directory of sensory organ deals by technology type 2007

Appendix 5 – Deal type definitions



About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

Order Form – Reports



Table of figures

Figure 1: Sensory organ partnering since 2007

Figure 2: Bigpharma – top 50 – sensory organ deals 2007 to 2013

Figure 3: Bigpharma sensory organ deal frequency – 2007 to 2013

Figure 4: Inactive bigpharma in sensory organ 2007-2013

Figure 5: Sensory organ partnering by deal type since 2007

Figure 6: Sensory organ partnering by industry sector since 2007

Figure 7: Sensory organ partnering by stage of development since 2007

Figure 8: Sensory organ partnering by technology type since 2007

Figure 9: Sensory organ partnering by dermatology target since 2007

Figure 10: Sensory organ deals with a headline value

Figure 11: Sensory organ deal headline value distribution, US$million – discovery stage

Figure 12: Sensory organ deal headline value distribution, US$million – preclinical stage

Figure 13: Sensory organ deal headline value distribution, US$million – phase I stage

Figure 14: Sensory organ deal headline value distribution, US$million – phase II stage

Figure 15: Sensory organ deal headline value distribution, US$million – phase III stage

Figure 16: Sensory organ deal headline value distribution, US$million – regulatory stage

Figure 17: Sensory organ deal headline value distribution, US$million – marketed stage

Figure 18: Summary median headline value by stage of development, 2007-2013

Figure 19 Sensory organ deals with upfront payment values

Figure 20: Sensory organ deal upfront payment distribution, US$million – discovery stage

Figure 21: Sensory organ deal upfront payment distribution, US$million – preclinical stage

Figure 22: Sensory organ deal upfront payment distribution, US$million – phase I stage

Figure 23: Sensory organ deal upfront payment distribution, US$million – phase II stage

Figure 24: Sensory organ deal upfront payment distribution, US$million – phase III stage

Figure 25: Sensory organ deal upfront payment distribution, US$million – regulatory stage

Figure 26: Sensory organ deal upfront payment distribution, US$million – marketed stage

Figure 27: Summary median upfront payments by stage of development, 2007-2013

Figure 28: Sensory organ deals with milestone payments

Figure 29: Sensory organ deal milestone distribution, US$million – discovery stage

Figure 30: Sensory organ deal milestone distribution, US$million – preclinical stage

Figure 31: Sensory organ deal milestone distribution, US$million – phase I stage

Figure 32: Sensory organ deal milestone distribution, US$million – phase II stage

Figure 33: Sensory organ deal milestone distribution, US$million – phase III stage

Figure 34: Sensory organ deal milestone distribution, US$million – regulatory stage

Figure 35: Sensory organ deal milestone distribution, US$million – marketed stage

Figure 36: Sensory organ deals with royalty rates, %

Figure 37: Sensory organ deal royalty rate distribution, US$million – discovery stage

Figure 38: Sensory organ deal royalty rate distribution, US$million – preclinical stage

Figure 39: Sensory organ deal royalty rate distribution, US$million – phase I stage

Figure 40: Sensory organ deal royalty rate distribution, US$million – phase II stage

Figure 41: Sensory organ deal royalty rate distribution, US$million – phase III stage

Figure 42: Sensory organ deal royalty rate distribution, US$million – regulatory stage

Figure 43: Summary median royalty rate by stage of development, 2007-2013

Figure 44: Top sensory organ deals by value since 2007

Figure 45: Top sensory organ deals signed by bigpharma value since 2007

Figure 46: Online partnering resources

Figure47: Forthcoming partnering events